• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy biomarkers: the long and winding road.

作者信息

Alban Tyler J, Chan Timothy A

机构信息

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH, USA.

Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Nat Rev Clin Oncol. 2021 Jun;18(6):323-324. doi: 10.1038/s41571-021-00498-w.

DOI:10.1038/s41571-021-00498-w
PMID:33727676
Abstract
摘要

相似文献

1
Immunotherapy biomarkers: the long and winding road.免疫治疗生物标志物：漫长而曲折的道路。
Nat Rev Clin Oncol. 2021 Jun;18(6):323-324. doi: 10.1038/s41571-021-00498-w.
2
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead.检查点抑制剂免疫相关毒性的生物标志物：当前进展和未来方向。
Expert Rev Mol Diagn. 2018 Mar;18(3):297-305. doi: 10.1080/14737159.2018.1440209. Epub 2018 Feb 15.
3
Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?癌症免疫学与免疫治疗中的有害细胞因子：生物标志物与靶点？
Ann Oncol. 2021 Nov;32(11):1311-1313. doi: 10.1016/j.annonc.2021.09.010. Epub 2021 Sep 21.
4
Radiomics to predict response to immunotherapy, bridging the gap from proof of concept to clinical applicability?放射组学用于预测免疫治疗反应，能否弥合从概念验证到临床应用的差距？
Ann Oncol. 2019 Jun 1;30(6):879-881. doi: 10.1093/annonc/mdz150.
5
Non-invasive biomarkers for monitoring the immunotherapeutic response to cancer.用于监测癌症免疫治疗反应的非侵入性生物标志物。
J Transl Med. 2020 Dec 9;18(1):471. doi: 10.1186/s12967-020-02656-7.
6
Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.肺癌的免疫检查点抑制剂治疗：新型药物、生物标志物和治疗模式。
Future Oncol. 2016 Feb;12(4):551-64. doi: 10.2217/fon.15.309. Epub 2016 Jan 18.
7
Endometrial Tumor Immune Response: Predictive Biomarker of Response to Immunotherapy.子宫内膜肿瘤免疫反应：免疫治疗反应的预测性生物标志物。
Clin Cancer Res. 2019 Apr 15;25(8):2366-2368. doi: 10.1158/1078-0432.CCR-18-4122. Epub 2019 Jan 28.
8
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.AML 和 MDS 中免疫疗法的最新进展：单克隆抗体和检查点抑制剂为临床实践铺平道路。
Adv Exp Med Biol. 2018;995:97-116. doi: 10.1007/978-3-030-02505-2_4.
9
Sepsis Biomarkers…The Long and Winding Road.脓毒症生物标志物……漫长而曲折的道路。
Crit Care Med. 2018 Jul;46(7):1194-1195. doi: 10.1097/CCM.0000000000003166.
10
Immunotherapy and NSCLC: The Long and Winding Road.免疫疗法与非小细胞肺癌：漫长而曲折的道路。
Cancers (Basel). 2020 Sep 4;12(9):2512. doi: 10.3390/cancers12092512.

引用本文的文献

1
An Overview of Analytical Approaches to Cancer Proteogenomics.癌症蛋白质基因组学分析方法概述
Methods Mol Biol. 2025;2921:93-118. doi: 10.1007/978-1-0716-4502-4_5.
2
The artificial intelligence revolution in gastric cancer management: clinical applications.胃癌管理中的人工智能革命：临床应用
Cancer Cell Int. 2025 Mar 21;25(1):111. doi: 10.1186/s12935-025-03756-4.
3
Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.靶向MEK/COX-2轴可提高PIK3CA过表达的错配修复缺陷型结直肠癌的免疫治疗疗效。
Cell Oncol (Dordr). 2024 Jun;47(3):1043-1058. doi: 10.1007/s13402-024-00916-y. Epub 2024 Feb 5.
4
KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.KLRG1 标记与肿瘤进展和免疫治疗反应相关的肿瘤浸润性 CD4 T 细胞亚群。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-006782.
5
A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.一种递送肿瘤源性抗原的生物器械组合产品可引发针对胶质母细胞瘤的免疫原性细胞死亡相关免疫应答。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-006880.
6
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy.免疫治疗时代去分化脂肪肉瘤的治疗。
Int J Mol Sci. 2023 May 31;24(11):9571. doi: 10.3390/ijms24119571.
7
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.通过浅层全基因组测序评估的循环肿瘤 DNA 的动态变化与 NSCLC 中检查点抑制剂的临床疗效相关。
Mol Oncol. 2023 May;17(5):779-791. doi: 10.1002/1878-0261.13409. Epub 2023 Mar 21.
8
Identification and Validation of Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.鉴定和验证突变作为黑色素瘤和非小细胞肺癌免疫检查点抑制剂治疗的反应指标。
Cells. 2022 Nov 30;11(23):3841. doi: 10.3390/cells11233841.
9
Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.肿瘤突变负荷与突变谱之间的相互作用及其对总生存期的影响：一项接受免疫检查点抑制剂治疗的转移性患者的初步研究
Cancers (Basel). 2022 Nov 4;14(21):5433. doi: 10.3390/cancers14215433.
10
Recent insights into crosstalk between genetic parasites and their host genome.近期对遗传寄生虫与其宿主基因组之间串扰的深入了解。
Brief Funct Genomics. 2024 Jan 18;23(1):15-23. doi: 10.1093/bfgp/elac032.